2.50

1.21% 0.03

Neumora Therapeutics Inc (NMRA)

Overview News Price History Option Chain Financials Why NMRA Down? Discussions Forecast

Neumora Therapeutics Inc stock is traded at $2.50, with a volume of 762.27K. It is up +1.21% in the last 24 hours and down -27.75% over the past month. Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Previous Close:

$2.47

Open:

$2.5

24h Volume:

762.27K

Relative Volume:

0.49

Market Cap:

$424.85M

Revenue:

Net Income/Loss:

$-236.30M

P/E Ratio:

-1.7085

EPS:

-1.4633

Net Cash Flow:

$-208.07M

1W Performance:

-5.30%

1M Performance:

-27.75%

6M Performance:

+47.06%

1Y Performance:

+119.30%

1-Day Range:

$2.465

$2.615

1-Week Range:

$2.41

$2.63

52-Week Range:

$0.611

$3.65

Neumora Therapeutics Inc Stock (NMRA) Company Profile

Name

Neumora Therapeutics Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

(857) 760-0900

Address

260 ARSENAL PLACE, SUITE 1, WATERTOWN

Employee

Twitter

Next Earnings Date

2026-03-30

Latest SEC Filings

NMRA's Discussions on Twitter

Compare NMRA vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NMRA Neumora Therapeutics Inc	2.50	419.75M	0	-236.30M	-208.07M	-1.4633
VRTX Vertex Pharmaceuticals Inc	454.97	115.58B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	79.23B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	43.59B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	43.26B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	31.97B	606.42M	-1.28B	-997.58M	-6.403

Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-17-26	Upgrade	William Blair	Mkt Perform → Outperform
Jan-12-26	Initiated	Leerink Partners	Outperform
Dec-01-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Oct-27-25	Upgrade	Guggenheim	Neutral → Buy
Sep-16-25	Downgrade	JP Morgan	Neutral → Underweight
Apr-02-25	Downgrade	BofA Securities	Buy → Underperform
Mar-10-25	Downgrade	William Blair	Outperform → Mkt Perform
Mar-07-25	Downgrade	Guggenheim	Buy → Neutral
Mar-07-25	Downgrade	Stifel	Buy → Hold
Jan-02-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-05-24	Downgrade	JP Morgan	Overweight → Neutral
Oct-01-24	Initiated	H.C. Wainwright	Buy
Jul-22-24	Initiated	Needham	Buy
Jul-08-24	Initiated	Mizuho	Outperform
Dec-12-23	Initiated	Deutsche Bank	Hold
Oct-10-23	Initiated	BofA Securities	Buy
Oct-10-23	Initiated	Guggenheim	Buy
Oct-10-23	Initiated	JP Morgan	Overweight
Oct-10-23	Initiated	RBC Capital Mkts	Outperform
Oct-10-23	Initiated	Stifel	Buy
Oct-10-23	Initiated	William Blair	Outperform

View All

Neumora Therapeutics Inc Stock (NMRA) Latest News

Mar 25, 2026

NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the ... - Bluefield Daily Telegraph

Mar 25, 2026

NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire

Mar 25, 2026

Neumora Therapeutic (NMRA.US) will release its earnings report on March 30. - Moomoo

Mar 25, 2026

Mar 24, 2026

If You Invested $1,000 in Neumora Therapeutics Inc (NMRA) - Stock Titan

Mar 24, 2026

Mar 22, 2026

Neumora Therapeutics stock jumps, analyst sees upside in Alzheimer's treatment - MSN

Mar 22, 2026

Mar 19, 2026

NMRA SEC FilingsNeumora Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 19, 2026

Mar 18, 2026

Neumora Therapeutics (NMRA) positioned to capitalize on blockbuster opportunity - MSN

Mar 18, 2026

Quarterly Trades: Is Neumora Therapeutics Inc forming a breakout pattern2026 Investor Takeaways & Daily Profit Maximizing Tips - baoquankhu1.vn

Mar 18, 2026

RBC sees upside potential in Neumora Therapeutics (NMRA) - MSN

Mar 18, 2026

Neumora reports promising Phase 1b results in Alzheimer’s agitation - MSN

Mar 18, 2026

Mar 17, 2026

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Short Interest Down 13.7% in February - MarketBeat

Mar 17, 2026

Mar 16, 2026

Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026 - The Manila Times

Mar 16, 2026

Mar 13, 2026

Neuropsych Drugmaker Wants Out Of Investors' IPO Data Suit - Law360

Mar 13, 2026

Mar 10, 2026

Neumora Therapeutics (NASDAQ:NMRA) Stock Price Up 8.2%What's Next? - MarketBeat

Mar 10, 2026

Mar 09, 2026

Neumora Therapeutics (NMRA) Positioned to Capitalize on Blockbuster Opportunity - Bitget

Mar 09, 2026

Mar 04, 2026